Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.91M | $2.44M | $4.82M | $36.1M | $3.94M | $882K | $0.00 | — | — | — |
| Revenue growth | — | 27.7% | 97.6% | 649.5% | -89.1% | -77.6% | -100.0% | — | — | — |
| Operating income | -$20.0M | -$32.6M | -$56.7M | -$77.1M | -$123M | -$56.0M | -$39.8M | -$45.1M | -$48.7M | -$85.3M |
| Operating margin | -1045.6% | -1334.4% | -1176.8% | -213.3% | -3119.2% | -6350.1% | — | — | — | — |
| Net income | -$20.0M | -$32.4M | -$55.7M | -$71.5M | -$111M | -$45.6M | -$42.3M | -$44.6M | -$40.2M | -$78.5M |
| Net margin | -1046.3% | -1328.6% | -1154.5% | -197.7% | -2826.1% | -5176.4% | — | — | — | — |
| EPS (diluted) | -$0.49 | -$0.65 | -$0.98 | -$1.12 | -$1.42 | -$11.15 | -$10.15 | -$10.31 | -$3.68 | -$5.90 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$13.6M | -$27.8M | -$30.1M | -$45.7M | -$99.7M | -$48.2M | -$37.5M | -$36.1M | -$41.8M | -$64.5M |
| Capital expenditures | $353K | $707K | $2.30M | $2.74M | $484K | $54.2K | $13.4K | $0.00 | $0.00 | $7.00K |
| Free cash flow | -$13.9M | -$28.5M | -$32.4M | -$48.5M | -$100M | -$48.2M | -$37.6M | -$36.1M | -$41.8M | -$64.5M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.0M | $62.5M | $41.7M | $31.7M | $85.4M | $25.0M | $17.0M | $13.7M | $17.2M | $28.5M |
| Total assets | $17.9M | $67.0M | $47.0M | $49.1M | $102M | $108M | $66.3M | $28.3M | $156M | $168M |
| Total liabilities | $8.97M | $9.19M | $19.5M | $43.0M | $57.0M | $38.6M | $33.3M | $35.2M | $13.5M | $20.7M |
| Long-term debt | — | — | — | — | $18.0M | $15.6M | $16.0M | $0.00 | — | — |
| Shareholders' equity | $8.92M | $57.8M | $27.5M | $6.16M | $45.3M | $69.1M | $33.0M | -$6.91M | $142M | $148M |
| Retained earnings | -$33.3M | -$65.7M | -$121M | -$193M | -$304M | -$350M | -$392M | -$437M | -$477M | -$555M |
| Shares (wtd avg diluted) | 44.7M | 55.6M | 57.2M | 64.7M | 78.1M | 4.09M | 4.17M | 4.33M | 10.9M | 13.3M |
Every figure is extracted from Corbus Pharmaceuticals Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.